VACCINEX INC
For the period ended Dec 31, 2023. Filed Apr 2, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 2, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Vaccinex, Inc. | ||
| Date: April 1, 2024 | By: | /s/ Maurice Zauderer, Ph.D. |
|---|---|---|
| Maurice Zauderer, Ph.D. | ||
| President and Chief Executive Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Maurice Zauderer, Ph.D. | President, Chief Executive Officer and Director | April 1, 2024 |
| Maurice Zauderer, Ph.D. | (Principal Executive Officer) | |
| /s/ Jill Sanchez, CPA | Chief Financial Officer | April 1, 2024 |
| Jill Sanchez, CPA | (Principal Financial and Accounting Officer) | |
| /s/ Albert D. Friedberg | Chairman of the Board | April 1, 2024 |
| Albert D. Friedberg | ||
| /s/ Chrystyna Bedrij Stecyk | Director | April 1, 2024 |
| Chrystyna Bedrij Stecyk | ||
| /s/ Jacob B. Frieberg | Director | April 1, 2024 |
| Jacob B. Frieberg | ||
| /s/ Bala S. Manian, Ph.D. | Director | April 1, 2024 |
| Bala S. Manian, Ph.D. | ||
| /s/ Gerald E. Van Strydonck | Director | April 1, 2024 |
| Gerald E. Van Strydonck | ||
| /s/ Barbara Yanni | Director | April 1, 2024 |
| Barbara Yanni | ||
INDEX TO FINANCIAL STATEMENTS
| Report of Independent Registered Public Accounting Firm (PCAOB ID No. 34) | F-2 |
|---|---|
| Balance Sheets as of December 31, 2023 and 2022 | F-4 |
| Statements of Operations and Comprehensive Loss for the Years ended December 31, 2023 and 2022 | F-5 |
| Statements of Stockholders’ Equity/(Deficit) for the Years ended December 31, 2023 and 2022 | F-6 |
| Statements of Cash Flows for the Years ended December 31, 2023 and 2022 | F-7 |
| Notes to Financial Statements | F-8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.